BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 27283899)

  • 1. Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
    Park SH; Chung YM; Ma J; Yang Q; Berek JS; Hu MC
    Oncotarget; 2016 Jul; 7(27):42110-42125. PubMed ID: 27283899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antipsychotic agent trifluoperazine hydrochloride suppresses triple-negative breast cancer tumor growth and brain metastasis by inducing G0/G1 arrest and apoptosis.
    Feng Z; Xia Y; Gao T; Xu F; Lei Q; Peng C; Yang Y; Xue Q; Hu X; Wang Q; Wang R; Ran Z; Zeng Z; Yang N; Xie Z; Yu L
    Cell Death Dis; 2018 Sep; 9(10):1006. PubMed ID: 30258182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
    Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
    Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
    Zhang L; Cai M; Gong Z; Zhang B; Li Y; Guan L; Hou X; Li Q; Liu G; Xue Z; Yang MH; Ye J; Chin YE; You H
    J Clin Invest; 2017 Jun; 127(6):2159-2175. PubMed ID: 28436938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.
    Camarda R; Zhou AY; Kohnz RA; Balakrishnan S; Mahieu C; Anderton B; Eyob H; Kajimura S; Tward A; Krings G; Nomura DK; Goga A
    Nat Med; 2016 Apr; 22(4):427-32. PubMed ID: 26950360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of ERRα suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin.
    Wu YM; Chen ZJ; Liu H; Wei WD; Lu LL; Yang XL; Liang WT; Liu T; Liu HL; Du J; Wang HS
    Oncotarget; 2015 Sep; 6(28):25588-601. PubMed ID: 26160845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment.
    Lu H; Tran L; Park Y; Chen I; Lan J; Xie Y; Semenza GL
    Cancer Res; 2018 Aug; 78(15):4191-4202. PubMed ID: 29880481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
    Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
    Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1.
    Liu R; Zhi X; Zhou Z; Zhang H; Yang R; Zou T; Chen C
    Sci Rep; 2018 Jan; 8(1):1138. PubMed ID: 29348684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
    Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
    Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression.
    Liu R; Shi P; Nie Z; Liang H; Zhou Z; Chen W; Chen H; Dong C; Yang R; Liu S; Chen C
    Theranostics; 2016; 6(4):533-44. PubMed ID: 26941846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
    Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
    FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating bioinformatics and experimental models to investigate the mechanism of the chelidonine-induced mitotic catastrophe via the AKT/FOXO3/FOXM1 axis in breast cancer cells.
    Li H; Tang X; Sun Z; Qu Z; Zou X
    Biomol Biomed; 2024 May; 24(3):560-574. PubMed ID: 37976368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5.
    Zhou W; Song F; Wu Q; Liu R; Wang L; Liu C; Peng Y; Mao S; Feng J; Chen C
    PLoS One; 2017; 12(4):e0176395. PubMed ID: 28437471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
    Lee KM; Giltnane JM; Balko JM; Schwarz LJ; Guerrero-Zotano AL; Hutchinson KE; Nixon MJ; Estrada MV; Sánchez V; Sanders ME; Lee T; Gómez H; Lluch A; Pérez-Fidalgo JA; Wolf MM; Andrejeva G; Rathmell JC; Fesik SW; Arteaga CL
    Cell Metab; 2017 Oct; 26(4):633-647.e7. PubMed ID: 28978427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.